Patisiran exposure in early pregnancy : a case report
© The Author(s), 2024..
We describe here the first case of exposure to patisiran treatment, a small interfering RNA molecule, during early pregnancy of a 36-year-old woman with symptomatic hereditary transthyretin-related amyloidosis. There were no major complications during pregnancy and delivery, except for a postpartum hemorrhage due to uterine atony. Vitamin A levels had to be closely monitored during pregnancy, and vitamin A substitution adapted accordingly. There was no sign of minor or major congenital abnormalities of the baby. One month after delivery, the patient showed slight clinical and electrophysiological signs of neuropathy progression due to patisiran treatment withdrawal. Patisiran infusions were resumed 3 months after delivery. Due to the unknown teratogenic potential of patisiran, the risk of neuropathy worsening associated with withholding treatment must of course be weighed against a potential teratogenic risk of treatment during pregnancy. Vitamin A levels need to be closely assessed, and substitution must be adapted accordingly, to avoid embryofetal adverse outcome due to vitamin A deficiency or toxicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Therapeutic advances in neurological disorders - 17(2024) vom: 01., Seite 17562864241239755 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Loser, Valentin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amyloidosis |
|---|
| Anmerkungen: |
Date Revised 28.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/17562864241239755 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370223551 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370223551 | ||
| 003 | DE-627 | ||
| 005 | 20240329001149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240328s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/17562864241239755 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM370223551 | ||
| 035 | |a (NLM)38532802 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Loser, Valentin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patisiran exposure in early pregnancy |b a case report |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), 2024. | ||
| 520 | |a We describe here the first case of exposure to patisiran treatment, a small interfering RNA molecule, during early pregnancy of a 36-year-old woman with symptomatic hereditary transthyretin-related amyloidosis. There were no major complications during pregnancy and delivery, except for a postpartum hemorrhage due to uterine atony. Vitamin A levels had to be closely monitored during pregnancy, and vitamin A substitution adapted accordingly. There was no sign of minor or major congenital abnormalities of the baby. One month after delivery, the patient showed slight clinical and electrophysiological signs of neuropathy progression due to patisiran treatment withdrawal. Patisiran infusions were resumed 3 months after delivery. Due to the unknown teratogenic potential of patisiran, the risk of neuropathy worsening associated with withholding treatment must of course be weighed against a potential teratogenic risk of treatment during pregnancy. Vitamin A levels need to be closely assessed, and substitution must be adapted accordingly, to avoid embryofetal adverse outcome due to vitamin A deficiency or toxicity | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Patisiran | |
| 650 | 4 | |a amyloidosis | |
| 650 | 4 | |a case report | |
| 650 | 4 | |a hATTR | |
| 650 | 4 | |a pregnancy | |
| 650 | 4 | |a siRNA | |
| 700 | 1 | |a Baumgartner, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Legardeur, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Panchaud, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Théaudin, Marie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic advances in neurological disorders |d 2008 |g 17(2024) vom: 01., Seite 17562864241239755 |w (DE-627)NLM192619276 |x 1756-2856 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g day:01 |g pages:17562864241239755 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/17562864241239755 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |b 01 |h 17562864241239755 | ||